NCT00145041View on ClinicalTrials.gov

Pharmacokinetic Study of Liposomal Vincristine in Patients With Malignant Melanoma & Hepatic Dysfunction

PHASE1CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

February 28, 2005

Primary Completion Date

September 30, 2007

Study Completion Date

November 30, 2007

Conditions
Malignant Melanoma
Interventions
DRUG

Vincristine Sulfate Liposomes Injection

Marqibo (VSLI) 1.0 mg/m2 delivered by intravenous infusion over 1 hour every 2 weeks.

Trial Locations (1)

77030

University of Texas M.D. Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
lead

Acrotech Biopharma Inc.

INDUSTRY